abstract |
This invention relates to dry power aerosol formulations for use with a dry powder inhaler, the formulation comprising the PDE 4 inhibitor N-cyclopropyl-1-[3-(1-oxido-3-pyridinylethynyl)phenyl]-1,4-dihydro[1,8] naphthyridin-4-one-3-carboxamide (Formula I), and sieved lactose for inhalation. |